Larimar Therapeutics (NASDAQ: LRMR) insider transactions
In the twelve months to 10 November 2026, executives and directors of Larimar Therapeutics reported 0 open-market sales and 8 open-market purchases of 5,160,000 shares ($25.7m), by 4 people, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 29 September 2026 | Harlow John B. Jr. | President and COO | Grant or award | +50,000 | — | 50,000 | Form 4 |
| 6 July 2026 | Hamilton Thomas Edward | Director | Open-market purchase | +50,000 | $3.34 | 714,798 | Form 4 |
| 27 February 2026 | Sherman Jeffrey W | Director | Open-market purchase | +5,000 | $5.00 | 5,000 | Form 4 |
| 27 February 2026 | Thomas Frank E | Director | Open-market purchase | +5,000 | $5.00 | 7,000 | Form 4 |
| 27 February 2026 | Hamilton Thomas Edward | Director | Open-market purchase | +100,000 | $5.00 | 664,798 | Form 4 |
| 27 February 2026 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +1,084,010 | $5.00 | 10,622,928 | Form 4 |
| 27 February 2026 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +1,084,012 | $5.00 | 10,622,957 | Form 4 |
| 27 February 2026 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +831,978 | $5.00 | 8,153,107 | Form 4 |
| 27 February 2026 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +2,000,000 | $5.00 | 6,207,982 | Form 4 |
| 26 January 2026 | Celano Michael | Chief Financial Officer | Grant or award | +37,604 | — | 215,785 | Form 4 |
| 26 January 2026 | Ben-maimon Carole | President and CEO | Grant or award | +100,100 | — | 368,276 | Form 4 |
| 26 January 2026 | Clayton Russell | Chief Medical Officer | Grant or award | +25,637 | — | 71,443 | Form 4 |
| 26 January 2026 | Shankar Gopi | Chief Development Officer | Grant or award | +25,637 | — | 76,443 | Form 4 |
| 31 July 2025 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +3,387,529 | $3.20 | 9,538,918 | Form 4 |
| 31 July 2025 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +3,387,539 | $3.20 | 9,538,945 | Form 4 |
| 31 July 2025 | Deerfield Mgmt HIF, L.P. | Director | Open-market purchase | +2,599,932 | $3.20 | 7,321,129 | Form 4 |
| 22 January 2025 | Celano Michael | Chief Financial Officer | Grant or award | +34,185 | — | 178,181 | Form 4 |
| 22 January 2025 | Ben-maimon Carole | President and CEO | Grant or award | +91,000 | — | 387,208 | Form 4 |
| 22 January 2025 | Clayton Russell | Chief Medical Officer | Grant or award | +23,306 | — | 45,806 | Form 4 |
| 22 January 2025 | Shankar Gopi | Chief Development Officer | Grant or award | +23,306 | — | 50,806 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Larimar Therapeutics page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.